New registry monitors noonan syndrome kids on growth hormone

NCT ID NCT05308927

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 30 times

Summary

This study is a registry that follows children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. It aims to collect long-term data on growth, safety, and quality of life. No new treatment is given; it simply observes real-world outcomes. About 221 children will be enrolled from French clinics.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NOONAN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ap-Hp-Hopital de Bicetre-2

    Le Kremlin-Bicêtre, 94275, France

  • Centre Hospitalier Universitaire D'Angers-2

    Angers, 49033, France

  • Hopital Des Enfants-2

    Toulouse, 31059, France

Conditions

Explore the condition pages connected to this study.